RNA antagonists targeting GLI2 for the treatment of leukemia
The present invention relates to oligomer compounds (oligomers) for the treatment and prevention of acute myeloid leukemia, which target GLI2 mRNA in a cell, leading to reduced expression of GLI2.
1. A method for treating acute myeloid leukaemia or pre-leukaemia, comprising administering to a patient an oligomer consisting of 10-30 nucleobases wherein the oligomer is perfectly complementary to a corresponding region of SEQ ID NO:1, all linkages between nucleobases are phosphorothioate linkages, and comprises nucleotide analogues having a modified sugar.
2. The method of claim 1 wherein the oligomer is not perfectly complementary along its entire length to any portion of SEQ ID NO:2.
3. The method of claim 1 wherein the oligomer comprises the sequence of SEQ ID NO:19.
4. The method of claim 1 wherein the is between 10-18 nucleobases in length.
5. The method of claim 1 wherein the nucleotide analogues having a modified sugar are selected from the group consisting of: Locked Nucleic Acid (LNA); 2′-O-alkyl-RNA, 2′-OMe-RNA, 2′-amino-DNA, and 2′-fluoro-DNA.
6. The method of claim 5 wherein the nucleotide analogues are LNA.
7. The method of claim 1 wherein the oligomer is a gapmer.
8. The method of claim 1 wherein the oligomer inhibits the expression of GL12 or GL12 mRNA in a cell which is expressing GL12 or GL12 mRNA.
9. The method of claim 1 wherein the oligomer comprises at least one non-nucleotide or non-polynucleotide moiety.
10. The method of claim 1 wherein the preleukemia is myelodysplastic syndrome or myeloproliferative disease.
11. The method of claim 1 wherein the oligomer comprises SEQ ID NOs: 112, 114, 118, 120, or 132.
12. The method of claim 1 wherein the oligomer is between 12-18 nucleobases in length.
13. The method of claim 1 wherein the oligomer is between 12-16 nucleobases in length.